Publications by authors named "F Almaguel"
Article Synopsis
- Prostate cancer (PCa) is the leading form of cancer (excluding skin cancer) in men, and recent advancements in imaging and treatment have improved the diagnosis and therapy options for those affected, particularly for advanced and metastatic cases.
- Advances in urea-based, small-molecule inhibitors targeting prostate-specific membrane antigen (PSMA) have shown promise in initial staging and detecting recurrent PCa, providing high specificity for identifying pelvic nodal involvement.
- A specific PSMA-targeted therapy has been linked to improved survival outcomes when used alongside standard treatments for patients with metastatic, castration-resistant PCa, suggesting new opportunities for more effective therapies in the future.
Radiopharmaceutical therapy using Lu-prostate-specific membrane antigen (PSMA) is an effective prostate cancer treatment that was recently approved by the U.S. Food and Drug Administration.
View Article and Find Full Text PDFHundreds of billions of commensal microorganisms live in and on our bodies, most of which colonize the gut shortly after birth and stay there for the rest of our lives. In animal models, bidirectional communications between the central nervous system and gut microbiota (Gut-Brain Axis) have been extensively studied, and it is clear that changes in microbiota composition play a vital role in the pathogenesis of various neurodevelopmental and neurodegenerative disorders, such as Autism Spectrum Disorder, Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, anxiety, stress, and so on. The makeup of the microbiome is impacted by a variety of factors, such as genetics, health status, method of delivery, environment, nutrition, and exercise, and the present understanding of the role of gut microbiota and its metabolites in the preservation of brain functioning and the development of the aforementioned neurological illnesses is summarized in this review article.
View Article and Find Full Text PDFArticle Synopsis
- Medicinal chemists aim to find effective drug candidates that can specifically inhibit enzymes, with boron-based compounds showing great promise due to their ability to interact with protein targets.
- Since the introduction of Velcade, the first boron-based drug, the range of such compounds has expanded significantly, including various classes of boron-containing drugs for multiple diseases.
- The review highlights the synthesis and biological activities of these drugs, which include a wide range of therapeutic effects, suggesting they could be key in developing new treatments with improved efficacy and fewer side effects.